Heart Failure Clinical Trial
Official title:
SCARF: Saxagliptin on CArdiac StRucture and Function
Diabetes is associated with a substantially increased risk of heart failure, which is associated with substantial morbidity and mortality. Despite the development of new therapeutic strategies to improve glycemic control, recent clinical data from the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study observed an unexpected finding of an excess of adjudicated heart failure hospitalizations. This excess occurred in the setting of pre-existing heart failure (HF) hospitalization and in those with elevated biomarkers for heart failure such as N terminal pro Brain type natriuretic peptide (NT-pro BNP). A wealth of preclinical data did not suggest a mechanistic basis for an excess of heart failure events, however these preclinical studies primarily focused upon prevention based strategies as opposed to regression studies once established heart failure was present. This proposal seeks to understand if and how dipeptidyl peptidase-4 inhibitors (DPP4i,specifically saxagliptin) may influence the development of heart failure, by evaluating changes in cardiac structure and function using cardiac magnetic resonance imaging (MRI).
The cardiovascular safety and potential cardioprotective effects of diabetes drugs have been
the focus of recent research. Currently, the Food and Drug Administration (FDA) requires all
new anti-diabetic drugs to demonstrate no important increase in cardiovascular adverse events
before approval.
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are oral incretin-based agents that
increase glucagon-like peptide-1 (GLP-1) level, with proven anti-hyperglycemic effects and
are increasingly used in the management of type 2 diabetes. In a rat model of diabetes and
myocardial infarction, sitagliptin treatment improved passive left ventricular compliance,
increased endothelial cell density, reduced myocyte hypertrophy and collagen abundance. GLP-1
and DDP-4 inhibition with vildagliptin improve cardiac function, cardiac remodeling, and
survival in animal models of pressure-overload and chronic heart failure. However, in another
study of post-MI cardiac remodeling in mice, vildagliptin failed to show any early or late
protective effects on cardiac function.
Some clinical studies suggest that GLP-1 infusion is associated with an absolute increase in
left ventricular ejection fraction (LVEF) in patients with heart failure, although data are
conflicting. The GLP-1 receptor analog, exenatide may reduce infarct size in patients with
myocardial infarction but does not improve LVEF.
The Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute
Coronary Syndrome EXAMINE trial randomized assigned 5340 patients with type 2 diabetes and
recent acute coronary syndrome to alogliptin or placebo, and found no increase in adverse
cardiovascular events in the alogliptin group. In SAVOR-TIMI 53, 16,492 patients with type 2
diabetes who had a history of, or were at risk for, cardiovascular events were randomized to
receive saxagliptin or placebo. Over a median follow-up of 2.1 years, the primary composite
endpoint of cardiovascular death, myocardial infarction, or ischemic stroke did not differ
significantly between the 2 groups (P=0.99 for superiority; P<0.001 for noninferiority).
However, patients in the saxagliptin group were more likely to be hospitalized for heart
failure, which was not ascertained in the EXAMINE trial. Furthermore, the Sitagliptin
Cardiovascular Outcome Study (TECOS), which examined the DPP4i sitagliptin versus placebo in
high risk patients for a cardiovascular event demonstrated cardiovascular safety (P<0.001 for
non inferiority), and there was no signal for excess heart failure hospitalizations.
Cardiac magnetic resonance imaging (CMR) has emerged as the "gold standard" for measuring LV
volume, mass, and ejection fraction. LV volume measurements by cardiac MRI do not rely on
geometric assumptions. CMR measurements have excellent intra-observer, inter-observer, and
inter-study variability, which were superior to other imaging techniques. The high
inter-study reproducibility of CMR affords a substantial reduction in the required sample
size to demonstrate even small changes in LV volume, LV mass or LVEF, or conversely, to
reliably exclude clinically important changes. Furthermore, CMR tagging allows detailed and
quantitative assessment of regional LV diastolic and systolic function. For example, in the
Multiethnic Study of Atherosclerosis (MESA), CMR can detect subtle alterations in global and
regional LV functions in patients with traditional and novel cardiovascular risk factors.
Although prior studies have failed to demonstrate any beneficial effects of improved glycemic
control on myocardial function, CMR promises to be a more sensitive and accurate technique.
Accordingly, the investigators propose to use CMR to examine the cardiac structure, global
and regional function among patients with type 2 diabetes treated with saxagliptin.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|